Search

Displaying results 1791 - 1800 of 7180 in total
  1. Indication

    Substance Addiction

    go.drugbank.com/conditions/DBCOND0033529
    Drugs: Valpromide
    Synonyms: Addiction to drugs
  2. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  3. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) … A barbiturate with hypnotic and sedative properties (but not antianxiety).

  4. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%
  5. Drug

    Methadone

    go.drugbank.com/drugs/DB00333
    ApprovedInvestigational

    Use of OAT is also intended to lead to social stabilization by reducing crime rates, incarceration, use of illicit opioids such as [heroin] or [fentanyl], and ultimately marginalization. … It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric toxicity compared to other opioids

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

  7. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP).

  8. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

  9. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    and resolve within 2 to 3 weeks. … [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7,

  10. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome